



To: All shareholders of IHH Healthcare Berhad

**ERRATA TO THE INTEGRATED ANNUAL REPORT 2024 OF IHH HEALTHCARE BERHAD
("IHH" OR "THE COMPANY")**

Dear Sir/Madam,

Reference is made to the Company's Integrated Annual Report 2024, which was issued to shareholders and submitted to Bursa Malaysia Securities Berhad (Announcement Reference No. DCS-24042025-00039) and Singapore Exchange Securities Trading Limited (Announcement Reference No. SG250429OTHR5FWH) on 29 April 2025.

Kindly be informed that amendments have been made to page 13 of the Company's Integrated Annual Report 2024 with respect to the financial performance in the Financial Highlights section and are detailed out below:

Ref	Before Amendment	After Amendment
Return on Equity (%) FY2022		
-Including Exceptional Items	6.4%	6.5%
-Excluding Exceptional Items	5.7%	5.8%
Return on Equity (%) FY2023		
-Including Exceptional Items	11.6%	10.7%
-Excluding Exceptional Items	5.0%	4.6%
Return on Total Assets (%) FY2023		
-Excluding Exceptional Items	2.6%	2.5%

Page 13 of the Company's Integrated Annual Report 2024 shall be amended accordingly pursuant to this Errata and is enclosed herewith for your reference.

Save for the abovementioned amendments, all other information contained in the Company's Integrated Annual Report 2024 remains unchanged.

Thank you.

Yours faithfully,

For and on behalf of IHH Healthcare Berhad

Dr. Prem Kumar Nair

Group Chief Executive Officer

Date: 22 May 2025

	FY2020	FY2021	FY2022	FY2023	FY2024
A. Income Statement (RM Million)					
Revenue by Strategic Business Units					
Singapore	3,887	5,033	4,913	5,573	6,131
Malaysia	2,187	2,727	3,074	3,684	4,154
India	2,656	3,729	3,175	3,555	4,028
Greater China	662	877	998	1,307	1,529
Türkiye and Europe	3,462	4,347	4,455	5,943	7,238
Southeast Asia	138	–	–	–	–
Hospital and Healthcare	12,992	16,713	16,615	20,062	23,080
IMU Health	249	258	261	54	–
Labs total revenue	–	–	1,662	1,665	1,779
Less: Labs inter-segment revenue	–	–	(603)	(685)	(747)
Labs ¹	–	–	1,059	980	1,032
Others ²	9	8	5	6	7
	13,250	16,979	17,940	21,102	24,119
PLife REIT total revenue	367	371	376	408	414
Less: PLife REIT inter-segment revenue	(212)	(218)	(227)	(255)	(266)
PLife REIT	155	153	149	153	148
	13,405	17,132	18,089	21,255	24,267
Hyperinflationary adjustment ³	–	–	(101)	(320)	116
Total	13,405	17,132	17,988	20,935	24,383
EBITDA⁴ by Strategic Business Units					
Singapore	1,359	1,693	1,484	1,627	1,825
Malaysia	556	760	847	937	1,060
India	201	665	492	600	723
Greater China	(147)	(70)	(60)	75	145
Türkiye and Europe	796	1,199	1,058	1,249	1,489
Southeast Asia	46	–	–	(2)	(2)
Hospital and Healthcare	2,811	4,247	3,821	4,486	5,240
IMU Health	76	87	85	13	–
Labs ¹	–	–	369	345	375
Others ²	(107)	(186)	(171)	(121)	(159)
Eliminations	–	–	9	–	(1)
	2,780	4,148	4,113	4,723	5,455
PLife REIT	309	350	278	326	291
Eliminations	(212)	(218)	(234)	(262)	(276)
	2,877	4,280	4,157	4,787	5,470
Hyperinflationary adjustment ³	–	–	(106)	(141)	(31)
Total	2,877	4,280	4,051	4,646	5,439
Profit After Tax and Minority Interest (“PATMI”)					
Including Exceptional Items	289	1,863	1,548	2,952	2,657
Excluding Exceptional Items	715	1,595	1,381	1,280	1,685
B. Financial Position (RM Million)					
Total Assets	44,534	45,510	48,467	50,192	56,759
Net Borrowings	7,441	5,856	7,170	7,672	13,270
Equity attributable to Owners of the Company	21,740	22,425	26,192	29,106	30,140
C. Financial Ratios					
Basic Earnings per Share (sen)					
Including Exceptional Items	2.27	20.20	17.00	33.52	30.17
Excluding Exceptional Items	7.13	17.15	15.09	14.53	19.13
Net Assets⁵ per Share (RM)					
	2.48	2.55	2.97	3.30	3.42
Net Tangible Assets⁶ per Share (RM)					
	0.87	0.94	1.16	1.35	1.16
Return on Equity⁷ (%)					
Including Exceptional Items	1.3%	8.4%	6.5%	10.7%	9.0%
Excluding Exceptional Items	3.2%	7.2%	5.8%	4.6%	5.7%
Return on Total Assets (%)					
Including Exceptional Items	0.6%	4.1%	3.2%	5.9%	4.7%
Excluding Exceptional Items	1.6%	3.5%	2.8%	2.5%	3.0%
Net Debt Equity Ratio⁸ (times)					
	0.28	0.21	0.25	0.24	0.39

Notes

The above financial summary may not be comparable across the periods presented due to the changes in the Group structure.

For changes in the accounting policies, adoption of new and/or revised accounting standards, as well as changes in presentation of financial statements for the current financial year, only the comparative figures for the previous year are restated to conform with the requirements arising from the said changes or adoption.

Comparative figures for the previous year are restated, where applicable, upon the completion of the Purchase Price Allocation on the Group's acquisitions of subsidiaries as required under MFRS 3, *Business Combinations*.

- Labs comprise the Group's diagnostic laboratory business. In the table above, prior to FY2022, Labs was classified as part of Malaysia, Singapore, India and Türkiye and Europe healthcare services.
- Others comprise mainly corporate offices as well as other investment holding entities.
- Arises from the application of MFRS 129, *Financial Reporting in Hyperinflationary Economies* for component entities whose functional currency is the Turkish Lira.
- Being earnings before interest, tax, depreciation, amortisation, exchange differences, share of results of associates and joint ventures and other non-operational items.
- Being net assets attributable to ordinary shareholders (excluding non-controlling interests).
- Being net assets attributable to ordinary shareholders (excluding non-controlling interests) less goodwill and intangible assets.
- Being PATMI for the year over average of equity attributable to owners of the Company as at year-end and beginning of the year.
- Debt includes loans and borrowings as well as lease liabilities and bank overdrafts.